Supriya Lifescience Q2 Results FY27: PAT Falls 42% to Rs 29.25 Cr, Revenue Up 3.24% to Rs 206.30 Cr
- November 6, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Supriya Lifescience Q2 Results FY27 were declared on 6 November 2026 on a Standalone basis. Revenue rose 3.24% YoY to Rs 206.30 Cr from Rs 199.83 Cr, while net profit fell 42% to Rs 29.25 Cr from Rs 50.43 Cr. Operating Profit declined 37.51% to Rs 45.40 Cr. These quarterly results show YoY growth in sales but lower profit for July to September 2026.
Supriya Lifescience Ltd (SUPRIYA) Q2 Results FY27 announced on 6 November 2026, covering the company’s financial performance for the July to September quarter. Supriya Lifescience Q2 Results FY27 show Standalone revenue of Rs 206.30 Cr and PAT of Rs 29.25 Cr. The results date and the standalone results basis frame every comparison below, since each figure is set against the same quarter a year earlier.
This Supriya Lifescience Q2 Results walkthrough turns the results analysis into five parts: financial highlights, business drivers, the FY27 outlook, risks and common questions. The Financial Highlights table that follows sets the quarter beside the year-earlier period, with the YoY change for each line. Univest follows these filings for NSE and BSE listed companies.
Click Here – Get Free Investment Predictions
Supriya Lifescience Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 206.3 Cr | Rs 199.83 Cr | +3.24% YoY |
| Operating Profit | Rs 45.4 Cr | Rs 72.65 Cr | -37.51% YoY |
| Net Profit (PAT) | Rs 29.25 Cr | Rs 50.43 Cr | -42% YoY |
Source: company filing for Supriya Lifescience Q2 Results FY27, 6 November 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Supriya Lifescience Q2 Results: What Stands Out
- Revenue of Rs 206.30 Cr is up 3.24% from Rs 199.83 Cr in the same quarter last year, a modest YoY growth figure.
- Net profit of Rs 29.25 Cr is 42% below the Rs 50.43 Cr reported a year ago, so profit moved against the sales trend.
- Operating Profit of Rs 45.40 Cr fell 37.51% from Rs 72.65 Cr, and the figures in Supriya Lifescience Q2 Results FY27 show the same direction.
- Net profit margin of 14.2% compares with 25.2% in the comparison quarter, based on the supplied net profit and revenue.
- Return on equity of 19.06% for FY26 and a debt-to-assets ratio of 0.00 are the balance sheet points; the performance analysis below links the numbers.
Supriya Lifescience Q2 Results FY27: Performance Analysis
Supriya Lifescience reported Standalone revenue of Rs 206.30 Cr for the quarter ended September 2026, up 3.24% YoY from Rs 199.83 Cr. Net profit came in at Rs 29.25 Cr against Rs 50.43 Cr a year earlier. Supriya Lifescience Q2 Results therefore show a small sales gain alongside a sharp profit decline.
The results analysis shows Operating Profit at Rs 45.40 Cr versus Rs 72.65 Cr, a fall of 37.51%, while net profit fell 42%. As a result, the net profit margin narrowed from 25.2% to 14.2%, a change Supriya Lifescience Q2 Results FY27 makes visible in the quarterly results table.
Investors reading the next filings will compare these YoY growth rates against later quarters of FY27 on the same standalone basis. The gap between 3.24% revenue growth and the 42% profit decline is the number to follow, and it leads into the business factors listed next.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue growth – The results analysis points to revenue growing 3.2% year on year to Rs 206.30 Cr in the latest quarter. This modest top-line gain was not enough to prevent the lower Operating Profit and net profit of the quarter.
Return measures – Return on equity was 19.06% in FY26 and return on capital employed was 25.30% in FY26. Within the quarterly results, these full-year figures show how the company used shareholder and employed capital over the year.
Debt position – The company is almost debt free, with a debt-to-assets ratio of 0.00 in FY26. This balance sheet position is part of the context for the quarter, alongside the revenue and return figures above.
FY27 Outlook After Supriya Lifescience Q2 Results
The FY27 outlook will take shape as the remaining quarters of the year are declared. For now, Supriya Lifescience Q2 Results FY27 cover only the July to September period, and the full-year picture will depend on later filings and conditions disclosed in them.
The net profit results analysis gives a reference point: Rs 29.25 Cr this quarter against Rs 50.43 Cr a year earlier. Readers can follow the Univest Screener for the next standalone filing from the company, which is the natural handover to the risks.
Key Risks to Watch After Supriya Lifescience Q2 Results FY27
YoY net profit decline
Net profit fell 42.0% year on year to Rs 29.25 Cr. Readers of the results should watch whether YoY growth in profit returns in later filings.
Narrower net profit margin
Net profit margin narrowed to 14.2% from 25.2% in the comparison quarter. Any reading of Supriya Lifescience Q2 Results FY27 should weigh this squeeze alongside the small revenue gain.
Volatile quarterly profit
Quarterly net profit has been volatile, ranging from Rs 24.04 Cr to Rs 74.23 Cr over the last 5 quarters. This range was flagged in the latest data and is worth tracking in future quarterly results.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Supriya Lifescience Q2 Results FY27 show Standalone revenue of Rs 206.30 Cr, up YoY, and net profit of Rs 29.25 Cr, down YoY. The quarterly results also carry flagged risks around the profit decline, the narrower margin and volatile earnings. Anyone weighing Supriya Lifescience Q2 Results on a standalone results basis should check the Univest app for updates and consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Supriya Lifescience Q2 Results FY27
What are Supriya Lifescience Q2 Results FY27?
Ans. Supriya Lifescience Q2 Results FY27 are the Standalone quarterly results of Supriya Lifescience for July to September 2026, with revenue of Rs 206.30 Cr and net profit of Rs 29.25 Cr, as the intro above explains.
What is the results date for Supriya Lifescience Q2 Results FY27?
Ans. The results date was 6 November 2026, when Supriya Lifescience declared its Q2 FY27 numbers, so the quarter ended September 2026 and the intro paragraphs set out the same date.
What revenue was reported in Supriya Lifescience Q2 Results FY27?
Ans. Supriya Lifescience reported revenue of Rs 206.30 Cr, compared with Rs 199.83 Cr a year earlier, which means revenue is up 3.24% as the Financial Highlights table shows.
What net profit was reported in Supriya Lifescience Q2 Results FY27?
Ans. Net profit came in at Rs 29.25 Cr against Rs 50.43 Cr in the same quarter last year, so profit fell 42%, a change the Key Takeaways section lists.
How much YoY growth did revenue show in Supriya Lifescience Q2 Results FY27?
Ans. Revenue showed YoY growth of 3.24% to Rs 206.30 Cr, while net profit moved the other way with a 42% decline, a comparison the Performance Analysis section sets out.
Did net profit rise or fall in Supriya Lifescience Q2 Results?
Ans. Net profit fell to Rs 29.25 Cr from Rs 50.43 Cr in the year-earlier quarter, a 42% decrease, alongside a net profit margin of 14.2% against 25.2%, as the risks section notes.
What was the Operating Profit in Supriya Lifescience Q2 Results FY27?
Ans. Supriya Lifescience posted Operating Profit of Rs 45.40 Cr, down 37.51% from Rs 72.65 Cr, which means it fell slightly less than net profit, per the Performance Analysis.
Are Supriya Lifescience Q2 Results consolidated results or standalone results?
Ans. Supriya Lifescience Q2 Results are standalone results, covering the company on its own, so every figure quoted here, including revenue of Rs 206.30 Cr, uses that basis throughout the article.
What business factors shaped Supriya Lifescience Q2 Results FY27?
Ans. Revenue growth of 3.2%, return on equity of 19.06% and a debt-to-assets ratio of 0.00 were the supplied factors, which the Key Business Factors section explains one by one.
What are the key risks after Supriya Lifescience Q2 Results FY27?
Ans. The flagged risks are a 42.0% net profit decline, a narrower margin of 14.2% and a quarterly profit range of Rs 24.04 Cr to Rs 74.23 Cr, as the Key Risks section details.
What is the outlook after Supriya Lifescience Q2 Results?
Ans. The FY27 full-year outcome depends on the quarters still to be declared, so these figures are one input, while the Outlook section explains what to track in the next filing.
Where can I find the complete Supriya Lifescience Q2 Results FY27 data?
Ans. Complete figures sit in the Financial Highlights table above, and the Univest Screener and Univest app list the company’s filings, which means readers can compare future results easily.
